Download PDF
Arzneimittelforschung 2008; 58(1): 1-10
DOI: 10.1055/s-0031-1296459
Review
Editio Cantor Verlag Aulendorf (Germany)

Melatonergic Drugs in Clinical Practice

Rüdiger Hardeland
1   Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, Göttingen, Germany
,
Burkhard Poeggeler
1   Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, Göttingen, Germany
,
Venkataramanujan Srinivasan
2   Department of Physiology, School of Medical Sciences, University Sains Malaysia, Kubang Kerian, Kota Bharu, Kelantan, Malaysia
,
Ilya Trakht
3   Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
,
Seithikurippu R Pandi-Perumal
3   Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
,
Daniel P Cardinali
4   Department of Physiology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

    Permissions and Reprints

Abstract

Melatonin (CAS 73-31-4) has both hypnotic and sleep/wake rhythm regulating properties. These sleep promoting actions, which are already demonstrable in healthy humans, have been found useful in subjects suffering from circadian rhythm sleep disorders (CRSD) like delayed sleep phase syndrome (DSPS), jet lag and shift-work sleep disorder. Low nocturnal melatonin production and secretion have been documented in elderly insomniacs, and exogenous melatonin has been shown to be beneficial in treating sleep disturbances of these patients. In comparison to a number of sleep-promoting compounds that are usually prescribed, such as benzodiazepines and z-drugs (Zolpidem and Zopiclon belonging to the latter ones), melatonin has several advantages of clinical value: it does not cause hangover nor withdrawal effects and is devoid of any addictive potential. However, recent meta-analyses revealed that melatonin is not sufficiently effective in treating most primary sleep disorders. Some of the reasons for a limited efficacy of this natural hormone are related to its extremely short half-life in the circulation, and to the fact that sleep maintenance is also regulated by mechanisms downstream of primary melatonergic actions. Hence, there is an urgent need for the development of melatonin receptor agonists with a longer half-life, which could be suitable for a successful treatment of insomnia. Such requirements are fulfilled by ramelteon (CAS 196597-26-9), which possesses a high affinity for the melatonin receptors MT1 and MT2 present in the circadian pacemaker, the suprachiasmatic nucleus (SCN). Ramelteon also has a substantially longer half-life than melatonin. This new drug has been successfully used in treating elderly insomniacs without any adverse effects reported, and is promising for treating patients with primary insomnia and also those suffering from CRSD. Since sleep disturbances constitute the most prevalent symptoms of various forms of depression, the need for the development of an ideal antidepressant was felt, which would both improve sleep and mitigate depressive symptoms. Since most of the currently used antidepressants, including the selective serotonin re-uptake inhibitors worsen the sleep disturbances of depressive patients, another novel melatonergic drug, agomelatine (CAS 138112-76-2), holds some promise because of its particular combination of actions: it has a high affinity for MT1 and MT2 receptors in the SCN, but it acts additionally as a 5-HT2C antagonist [5-hydroxytryptamine (serotonin) receptor 2C antagonist]. The latter property, which is decisive for the antidepressive action, would not favor but potentially antagonize sleep, but this is overcome during night by the melatonergic, sleep-promoting effect. This drug has been found beneficial in treating patients with major depressive and seasonal affective disorders. Unlike the other antidepressants, agomelatine improves both sleep and clinical symptoms of depressive illness and does not have any of the side effects on sleep seen with other compounds in use. This property seems to be of particular value because of the aggravating effects of disturbed sleep in the development of depressive symptoms. Based on these facts, agomelatine seems to be a drug of superior efficacy with a promising future in the treatment of depressive disorders. However, long-term safety studies are required for both ramelteon and agomelatine, with a consideration of the pharmacology of their metabolites, their effects on redox metabolism, and of eventual undesired melaton-ergic effects, e. g., on reproductive functions. According to current data, both compounds seem to be safe during short-term treatment.

Key words

Agomelatine - Antidepressants - Chrono-hypnotic drugs - Melatonergic agonists - Melatonin - Ramelteon - Serotonin - Sleep promotion
 

  • References

  • 1 Lerner AB, Case JD, Heinzelman RW. The structure of melatonin. J Am Chem Soc. 1959; 81: 6084-6085
    PubMedGoogle Scholar
  • 2 Hardeland R, Fuhrberg B. Ubiquitous melatonin – Presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol. 1996; 2: 25-45
    PubMedGoogle Scholar
  • 3 Tan D-X, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM et al. Melatonin – a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003; 34: 75-78
    CrossrefPubMedGoogle Scholar
  • 4 Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond). 2005; 2 (article no. 22) [DOI 10.1186/1743-7075-2-22]
    PubMedGoogle Scholar
  • 5 Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature’s most versatile biological signal?. FEBS J. 2006; 273: 2813-2838
    CrossrefPubMedGoogle Scholar
  • 6 Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem. 2003; 85: 1101-1108
    CrossrefPubMedGoogle Scholar
  • 7 Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J. 2006; 20: 1564-1566
    CrossrefPubMedGoogle Scholar
  • 8 Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. 1993; 49: 654-664
    CrossrefPubMedGoogle Scholar
  • 9 Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology. 2002; 143: 84-90
    CrossrefPubMedGoogle Scholar
  • 10 Hardeland R, Pandi-Perumal SR, Cardinali DP. Molecules in focus – Melatonin. Int J Biochem Cell Biol. 2005; 38: 313-316
    PubMedGoogle Scholar
  • 11 Foster RG, Hankins M, Lucas RJ, Jenkins A, Munoz M, Thompson S et al. Non-rod, non-cone photoreception in rodents and teleost fish. Novartis Found Symp. 2003; 253: 3-23
    PubMedGoogle Scholar
  • 12 Foster RG. Seeing the light … in a new way. J Neuroendocrinol. 2004; 16: 179-180
    CrossrefPubMedGoogle Scholar
  • 13 Dkhissi-Benyahya O, Gronfier C, De Vanssay W, Flamant F, Cooper HM. Modeling the role of mid-wavelength cones in circadian responses to light. Neuron. 2007; 53: 677-687
    CrossrefPubMedGoogle Scholar
  • 14 Moore RY. Neural control of the pineal gland. Behav Brain Res. 1996; 73: 125-130
    PubMedGoogle Scholar
  • 15 Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005; 437: 1257-1263
    Google Scholar
  • 16 Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure and the sleep EEG. J Biol Rhythms. 1997; 12: 627-635
    CrossrefPubMedGoogle Scholar
  • 17 Krauchi K, Wirz-Justice A. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology. 2001; 25: S92-S96
    CrossrefPubMedGoogle Scholar
  • 18 Gauer F, Masson-Pévet M, Stehle J, Pévet P. Daily variations in melatonin receptor density of rat pars tuberalis and suprachiasmatic nuclei are distinctly regulated. Brain Res. 1994; 641: 92-98
    CrossrefPubMedGoogle Scholar
  • 19 Pévet P, Bothorel B, Slotten H, Saboureau M. The chrono-biotic properties of melatonin. Cell Tissue Res. 2002; 309: 183-191
    CrossrefPubMedGoogle Scholar
  • 20 Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol. 2001; 280: C110-C118
    PubMedGoogle Scholar
  • 21 Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005; 27: 101-110
    CrossrefPubMedGoogle Scholar
  • 22 Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic clock. Neuron. 1997; 19: 91-102
    CrossrefPubMedGoogle Scholar
  • 23 Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM et al. Targeted disruption of the mouse Mel1b melatonin receptor. Mol Cell Biol. 2003; 23: 1054-1060
    CrossrefPubMedGoogle Scholar
  • 24 von CGall, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002; 309: 151-162
    CrossrefPubMedGoogle Scholar
  • 25 Hardeland R. Antioxidative protection by melatonin -Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005; 27: 119-130
    CrossrefPubMedGoogle Scholar
  • 26 Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C et al. Sleep inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995; 57: 552-558
    CrossrefPubMedGoogle Scholar
  • 27 Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2–4h before habitual bedtime, on sleep in normal young humans. Sleep. 1996; 19: 423-131
    PubMedGoogle Scholar
  • 28 Mendelson WB. Efficacy of melatonin as a hypnotic agent. J Biol Rhythms. 1997; 12: 651-656
    CrossrefPubMedGoogle Scholar
  • 29 Mendelson WB. A critical evaluation of the hypnotic efficacy of melatonin. Sleep. 1997; 20: 916-919
    PubMedGoogle Scholar
  • 30 Buscemi N, Van der meer B, Hooton N, Pandya R, Tjosvold L, Hartling L et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: A meta-analysis. J Gen Intern Med. 2005; 20: 1151-1158
    Google Scholar
  • 31 Buscemi N, Van der meer B, Hooton N, Pandya R, Tjosvoid L, Hartling L et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders accompanying sleep restriction. BMJ. 2006; 332: 385-393
    CrossrefPubMedGoogle Scholar
  • 32 Gorfine T, Assaf Y, Goshen-Gottstein Y, Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage. 2006; 31: 410-418
    CrossrefPubMedGoogle Scholar
  • 33 Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000; 25: 48-52
    PubMedGoogle Scholar
  • 34 Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relationship to the response to melatonin replacement therapy. Am J Med. 2004; 116: 91-9s5
    PubMedGoogle Scholar
  • 35 Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994; 91: 1824-1828
    CrossrefPubMedGoogle Scholar
  • 36 Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled release melatonin. Lancet. 1995; 346: 541-544
    CrossrefPubMedGoogle Scholar
  • 37 Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995; 18: 598-603
    PubMedGoogle Scholar
  • 38 Monti JM, Alvarino F, Cardinali DP, Savio I, Pintos A. Polysomnographic study of the effects of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriar. 1999; 28: 85-98
    PubMedGoogle Scholar
  • 39 Zhdanova IV, Wurtman RJ, Regan MM, Taylor J, Shi JP, Le-clair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001; 86: 4727-4730
    CrossrefPubMedGoogle Scholar
  • 40 Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005; 9: 25-39
    CrossrefPubMedGoogle Scholar
  • 41 Arendt J, Skene DJ, Middeleton B, Lockley SW, Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms. 1997; 12: 604-617
    CrossrefPubMedGoogle Scholar
  • 42 Lewy AJ, Sack RL. Exogenous melatonin’s phase-shifting effects on the endogenous melatonin profile in sighted humans: a brief review and critique of the literature. J Biol Rhythms. 1997; 12: 588-594
    CrossrefPubMedGoogle Scholar
  • 43 Cardinali DP, Brusco LI, Lloret SP, Furio AM. Melatonin in sleep disorders and jet lag. Neuroendocrinal Lett. 2002; 23 (Suppl 1) 9-13
    PubMedGoogle Scholar
  • 44 Cardinali DP, Furio AM, Reyes MP, Brusco LI. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control. 2006; 17: 601-609
    CrossrefPubMedGoogle Scholar
  • 45 Srinivasan V, Smits MG, Kayumov L, Pandi-Perumal SR, Cardinali DP, Thorpy MJ. Melatonin in circadian rhythm sleep disorders. In: Cardinali DP, Pandi-Perumal SR, eds Neuroendocrine Correlates of Sleep/Wakefulness. New York: Springer; 2006. p. 269-294
    CrossrefGoogle Scholar
  • 46 Hack LM, Lockley SW, Arendt J, Skene DJ. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. J Biol Rhythms. 2003; 18: 420-429
    CrossrefPubMedGoogle Scholar
  • 47 Skene DJ, Arendt J. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med. 2007; 8: 651-655
    CrossrefPubMedGoogle Scholar
  • 48 Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004; 5: 523-532
    CrossrefPubMedGoogle Scholar
  • 49 Miyamoto M, Nishikawa H, Ohta H, Uchikawa O, Ohkawa O, Ohkawa S. Behavioural pharmacology of TAK-375 in small animals. Ann Neurol. 2003; 54: S46
    PubMedGoogle Scholar
  • 50 Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005; 48: 301-310
    CrossrefPubMedGoogle Scholar
  • 51 McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005; 19: 1057-1065
    CrossrefPubMedGoogle Scholar
  • 52 Macías M, Escames G, Leon J, Coto A, Sbihi Y, Osuna A et al. Calreticulin — melatonin. An unexpected relationship. Eur J Biochem. 2003; 270: 832-40
    CrossrefPubMedGoogle Scholar
  • 53 Carlberg C. Gene regulation by melatonin. Ann NY Acad Sci. 2000; 917: 387-396
    PubMedGoogle Scholar
  • 54 Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for the treatment of insomnia. J Clin Pharmacol. 2006; 46: 140-148
    PubMedGoogle Scholar
  • 55 Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005; 9: 11-24
    CrossrefPubMedGoogle Scholar
  • 56 Huether G, Messner M, Rodenbeck A, Hardeland R. Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J Pineal Res. 1998; 24: 146-151
    CrossrefPubMedGoogle Scholar
  • 57 Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res. 2004; 1027: 59-66
    CrossrefPubMedGoogle Scholar
  • 58 France CR, Weltman RH, Koek W, Cruz CM, McMohan LR. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatto): dependence liability studies. Behav Neurosci. 2006; 120: 535-541
    CrossrefPubMedGoogle Scholar
  • 59 Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: the use of melatonergic agonists for the treatment of insomnia –focus on ramelteon. Nat Clin Pract Neurol. 2007; 3: 221-228
    CrossrefPubMedGoogle Scholar
  • 60 Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang I, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006; 7: 312-318
    CrossrefPubMedGoogle Scholar
  • 61 Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study on ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007; 23: 1005-1014
    CrossrefPubMedGoogle Scholar
  • 62 Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang I, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects wth chronic insomnia. J Clin Sleep Med. 2007; 3: 495-504
    PubMedGoogle Scholar
  • 63 Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath. 2007; 11: 159-164
    CrossrefPubMedGoogle Scholar
  • 64 Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006; 7: 17-24
    CrossrefPubMedGoogle Scholar
  • 65 Zee PC, Manthena P. The brain’s master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev. 2007; 11: 59-70
    CrossrefPubMedGoogle Scholar
  • 66 Kupfer J, Thase ME. The use of the sleep laboratory in the diagnosis of affective disorders. Psychiatr Clin North Am. 1983; 6: 3-25
    PubMedGoogle Scholar
  • 67 Riemann D, Berger M, Voderholzer U. Sleep and depression –results from psycho-biological studies: an overview. Biol Psychol. 2001; 57: 67-103
    CrossrefPubMedGoogle Scholar
  • 68 Lam RW. Sleep disturbances and depression. A challenge for antidepressants. Int Clin Psychopharmacol. 2006; 21: S25-S29
    CrossrefPubMedGoogle Scholar
  • 69 Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand. 2007; 115 (Suppl 433) 104-115
    CrossrefPubMedGoogle Scholar
  • 70 Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR et al. Melatonin in mood disorders. World J Psychiatry. 2006; 7: 138-151
    PubMedGoogle Scholar
  • 71 Venkobarao A, Parvathi devi S, Srinivasan V. Urinary melatonin in depression. Indian J Psychiatry. 1983; 25: 165-172
    PubMedGoogle Scholar
  • 72 Thompson C, Mezey G, Corn T, Franey C, English J, Arendt J et al. The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiatry. 1985; 147: 389-393
    CrossrefPubMedGoogle Scholar
  • 73 Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988; 45: 150-154
    CrossrefPubMedGoogle Scholar
  • 74 Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci USA. 2006; 103: 7414-7419
    CrossrefPubMedGoogle Scholar
  • 75 Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol. 2006; 16: S639-S643
    CrossrefPubMedGoogle Scholar
  • 76 Bourin M, Mocaër E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci. 2004; 29: 126-133
    PubMedGoogle Scholar
  • 77 Chagraoui A, Protais P, Filloux T, Mocaër E. Agomelatine (S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl). 2003; 170: 17-22
    CrossrefPubMedGoogle Scholar
  • 78 Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tan-credi A, Pasteau V et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003; 306: 954-964
    CrossrefPubMedGoogle Scholar
  • 79 Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006; 2: S31-S35
    PubMedGoogle Scholar
  • 80 Leproult R, Van Onderbergen A, L’Hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf). 2005; 63: 298-304
    CrossrefPubMedGoogle Scholar
  • 81 Pjrek E, Winkler D. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology. 2007; 190: 575-579
    CrossrefPubMedGoogle Scholar
  • 82 Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti JM. Could agomelatine be the ideal antidepressant?. Expert Rev Neurotherapeutics. 2006; 6: 1595-1608
    CrossrefPubMedGoogle Scholar
  • 83 Lôo H, Hale A, D’Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and the selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002; 17: 239-247
    CrossrefPubMedGoogle Scholar
  • 84 Kennedy SH, Emsley R. Placebo controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006; 16: 93-100
    CrossrefPubMedGoogle Scholar
  • 85 Olié JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007; 10: 661-673
    PubMedGoogle Scholar
  • 86 Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur Neuropsychopharmacol. 2005; 15: S419-S420
    PubMedGoogle Scholar
  • 87 Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs. 2006; 20: 981-9s92
    CrossrefPubMedGoogle Scholar
  • 88 Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007; 10: 691-696
    PubMedGoogle Scholar
  • 89 Den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol. 2006; 21: S21-S24
    CrossrefPubMedGoogle Scholar
  • 90 Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. Agomelatine, a new antidepressant induces regional changes in hippocampal neurogenesis. Biol Psychiatry. 2006; 59: 1087-1096
    CrossrefPubMedGoogle Scholar
  • 91 Regrigny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I. Melatonin improves cerebral circulation security margin in rats. Am J Physiol. 1998; 275: H139-H144
    PubMedGoogle Scholar
  • 92 Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. J Androl. 2002; 23: 572-578
    PubMedGoogle Scholar
  • 93 Silman RE, Leone RM, Hooper RJ, Preece MA. Melatonin, the pineal gland and human puberty. Nature. 1979; 282: 301-303
    CrossrefPubMedGoogle Scholar
  • 94 Luboshitzky R, Herer P, Shen-Orr Z. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment. Exp Clin Endocrinol Diabetes. 2004; 112: 102-107
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs. 2005; 6: 114-121
    PubMedGoogle Scholar
  • 96 Bogaards JJ, Hissink EM, Briggs M, Weaver R, Jochemsen R, Jackson P et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci. 2000; 12: 117-24
    CrossrefPubMedGoogle Scholar